Experienced in Chronic Inflammatory Demyelinating Polyneuropathy

Falk Hiepe

Berlin, BE, DE 
Experienced in Chronic Inflammatory Demyelinating Polyneuropathy
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Falk Hiepe practices in Berlin, Germany. Hiepe is rated as an Experienced expert by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. Their top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Glomerulonephritis, Vasculitis, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 110 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Chronic Inflammatory Demyelinating Polyneuropathy.

Locations

Berlin, BE 10117, Germany
Other Locations
Mitte, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

110 Total Publications

Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases.
Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases.
Journal: Arthritis research & therapy
Published: April 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hiepe's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile